IL6 and cancer: The increased leukocytosis underlines robust cancer-associated systemic inflammation as evidenced also by increased plasma concentration of pro-inflammatory cytokines, e.g. interleukin 6 (IL-6), as reported earlier in the same model of 4T1 tumour-bearing mice (Buczek et al., 2018).